Ixekizumab
Synonym(s)
DefinitionThis section has been translated automatically.
Ixekizumab is a humanized synthetically produced IgG4 monoclonal antibody with a molecular weight of 146 kDa. Ixekizumab has immunosuppressive and anti-inflammatory effects and is used for the treatment of moderate to severe plaque psoriasis.
Spectrum of actionThis section has been translated automatically.
Ixekinumab binds with high affinity to interleukin-17A (IL-17A) and inhibits interaction with the IL-17 receptor. IL-17A is a pro-inflammatory cytokine secreted by Th17 helper cells. IL-17a is involved in the inflammatory response in psoriasis. Binding of the antibody leads to inhibition of keratinocyte activation and proliferation. The half-life of ixekinumab is 13 days.
In the SPIRIt-P2 study, in which 363 patients worldwide participated, it was demonstrated that patients with confirmed psoriatic arthritis (CASPAR criteria) can still be treated effectively after unsuccessful therapy with TNF-alpha blockers.
Dosage and method of useThis section has been translated automatically.
The recommended dose is initially 160 mg by s.c.(2x 80 mg injections), followed by 80 mg (1 injection) in weeks 2, 4, 6, 8, 10 and 12; the subsequent maintenance dose is 80 mg (1 injection) every 4 weeks.
Undesirable effectsThis section has been translated automatically.
The drug is administered as a subcutaneous injection. The most common potential adverse effects include upper respiratory tract infections and reactions at the injection site.
PreparationsThis section has been translated automatically.
Taltz®.
Note(s)This section has been translated automatically.
Ixekizumab was approved in the USA, the EU and Switzerland in 2016 as an injection solution in a pre-filled pen and a pre-filled syringe. In Germany, the preparation has been available since March 2017. The antibody against IL-17A is indicated and well effective in moderate to severe plaque psoriasis (Blauvelt A et al. 2018)
LiteratureThis section has been translated automatically.
- Blauvelt A et al (2018) Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatolog Treat 29:220-229.
- Farahnik B et al (2016) Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther 6: 25-37
- Leonardi C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190-11999
- Nash P et al (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389:2317-2327.
- Ren V et al (2013) Potential role of ixekizumab in the treatment of moderate to severe plaque psoriasis. Clin Cosmet Investig Dermatol 6: 75-80
- Wang CQ et al (2014) IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol 134: 2990-2993